Hims & Hers Health has agreed to stop selling compound versions of Novo Nordisk’s Wegovy and other weight-loss drugs, ending ...

The agreement brings an end to the legal dispute between the two companies. Hims & Hers shares jumped.

By Stine Jacobsen and Maggie Fick COPENHAGEN, March 9 (Reuters) - Novo Nordisk has agreed to sell its blockbuster Wegovy and Ozempic drugs through U.S. telehealth company Hims & Hers' platform, the ...

Hims & Hers stock traded more than 40% higher after the deal was announced.

Hims & Hers shares jumped more than 50% in premarket trade on Monday after ending a dispute with Novo Nordisk by striking a partnership with the Danish drug giant.

Both companies’ stocks rose in the wake of the news.

Novo Nordisk drops its lawsuit against Hims & Hers as the companies partner to offer FDA-approved Wegovy and Ozempic through the telehealth platform.

March 9 (Reuters) - Hims & Hers' shares were up over 40% on Monday, after Novo Nordisk agreed to sell its blockbuster Wegovy ...

Telehealth company Hims & Hers on Monday announced a “strategic shift” in its business model, partnering with pharmaceutical company Novo Nordisk to sell its blockbuster GLP-1 medication and stop ...

Shares of Hims & Hers jumped as much as 55% Monday after Novo Nordisk announced it is dropping its lawsuit over Ozempic and Wegovy copycat drugs.

Novo is asking the court to permanently ban Hims from selling compounded versions of its drugs that infringe patents, and is seeking to recover damages.

The Danish drugmaker sued Hims in February over compounded versions of the Wegovy weight-loss pill that Hims launched and ...